SBIR/STTR Research Award

Tools for Accelerating R&D for Historically Understudied Protein Kinases

Award identifier ba7daa89f0e112682f9ea60fa419e8d3671aa772ee74c59b10656f55196b3586Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,408,440

Program and phase

SBIR · Phase II – Direct to Phase II

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LUCEOME BIOTECHNOLOGIES, L.L.C.
Proposal award date
2017-02-01
Contract end date
2020-01-31
UEI
PTPNMPNRP5R1
Solicitation number
PAR14-088
Topic code
NCATS

Research abstract

Protein kinases are central players in almost every aspect of human physiology and serve as critical mediators of signal transductionThe dysfunction of many kinases is implicated in cancerdiabetesinflammationand cardiovascular diseases and many are validated targets for therapeutic interventionThe human genome encodesprotein kinasesYettheor so marketed protein kinase drugstarget only a small fraction of the human kinomeA greater portion remains unexploredwith very little information available on their role in cell signalingChemical tools can play a pivotal role in target discovery and validationSelective and potent small molecule kinase inhibitors can be used to address this knowledge gap by pharmacological knockdown of a target protein kinase in their native environment and probe the effect of inhibition on cell signaling and disease pathologyOur goal is to systematically focus on the vast number of historically understudied kinaseswhich are currently non druggable due to lack of mechanistic and functional understanding due to a paucity of reagents and associated assays to gauge selectivityThis gap will be addressed by high quality chemical probe developmentcapable of selectively interrogating function of target kinasesDuring the Phase II periodwe will iteratively adevelop low costrobust assays using our platform split luciferase technology for the understudied kinases andbdevelop highquality chemical probeswhich can help deconvolute kinase biology and target discoveryThe chemical probe sets developed under this grant will be available as a resource to the research community

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

12 SBIR/STTR records share this UEI (2009–2023). Reported award amounts total $9,994,171. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.